Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001302997 | SCV001492227 | uncertain significance | Intellectual disability, autosomal dominant 1 | 2020-04-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces glycine with cysteine at codon 1079 of the MBD5 protein (p.Gly1079Cys). The glycine residue is highly conserved and there is a large physicochemical difference between glycine and cysteine. This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with MBD5-related conditions. |
Ambry Genetics | RCV004987046 | SCV005618163 | uncertain significance | Inborn genetic diseases | 2024-11-21 | criteria provided, single submitter | clinical testing | The c.3235G>T (p.G1079C) alteration is located in exon 12 (coding exon 7) of the MBD5 gene. This alteration results from a G to T substitution at nucleotide position 3235, causing the glycine (G) at amino acid position 1079 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |